The Food and Drug Administration (FDA) is announcing the following public workshop entitled ``Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology.'' The purpose of the public workshop is to engage stakeholders and solicit input from experts in oncology precision medicine on how to best weigh and evaluate evidence for classification and interpretation of sequencing results for precision oncology.
Document
Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology; Public Workshop
The Food and Drug Administration (FDA) is announcing the following public workshop entitled ``Weighing the Evidence: Variant Classification and Interpretation in Precision Oncol...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 56245
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology; Public Workshop,” thefederalregister.org (November 28, 2017), https://thefederalregister.org/documents/2017-25584/weighing-the-evidence-variant-classification-and-interpretation-in-precision-oncology-public-workshop.